U.S. drugmaker Eli Lilly (LLY.N), is expected to lose 20% of its global revenue around, because next year the focus of drug patents expired, suspended for most of the increase in basic salaries of employees in 2014 to cut costs.
Eli Lilly and Company at the end of the current year, the largest product, the antidepressant Cymbalta, will lose patent protection, and its 1 billion dollar a year's osteoporosis drug Evista cottage form is due to arrive in early 2014.
The company also decided to reduce employee bonuses in 2015, their 2014 performance.
News came just months after the pharmaceutical company decided to lay off about 1,000 domestic sales representatives, in order to reduce costs.
"This is a difficult but necessary decision," a company spokesman said on Wednesday, in charge of Edward Sagebiel. "We will continue in our history, the most significant challenges facing."
"While we have taken a number of measures to reduce costs and become a leaner organization, we must do more," Sagebiel said, adding that the company expects to save about 2016 with the help of $ 400 million, these cost-cutting efforts.
Sagebiel said Lilly employees will be eligible in 2015 base salary increases.
 



Other News:
Eli Lilly to freeze employee base pay ahead of generic onslaught
Shareholders voting on $24.4 billion Dell buyout
A look at the next steps for Detroit
China hikes tariff on US, Korean solar polysilicon
Exclusive: GM delays Chevy Cruze debut by a year
Asiana no longer suing San Francisco TV station
Zimmerman cleared; attorney says safety a concern
Battery in Honeywell locator eyed in 787 fire: source